Literature DB >> 15479690

Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins.

O Núñez1, A Fernández-Martínez, P L Majano, A Apolinario, M Gómez-Gonzalo, I Benedicto, M López-Cabrera, L Boscá, G Clemente, C García-Monzón, P Martín-Sanz.   

Abstract

BACKGROUND: Cyclooxygenase 2 (COX-2) and matrix metalloproteinases (MMPs) have been implicated in tissue injury and fibrogenesis in animal models but little is known regarding their role in hepatitis C virus (HCV) related liver disease in humans. AIMS: To characterise the intrahepatic expression pattern of COX-2 and MMPs in chronic HCV infection and determine whether HCV core and NS5A proteins could promote their expression in cultured hepatocyte derived cell lines. PATIENTS: Thirty two anti-HCV+ and 10 anti-HCV- patients were studied.
METHODS: Western blot, reverse transcription-polymerase chain reaction (RT-PCR), enzyme immunoassay, and immunohistochemistry were used to assess the expression pattern of COX-2 and MMPs in liver biopsy samples from all patients. COX-2 gene expression and MMP-9 protein levels were also determined by immunoblot, RT-PCR, and luciferase assays in core and NS5A transfected hepatocyte derived cells.
RESULTS: The intrahepatic expression level of COX-2, MMP-2, and MMP-9 was significantly higher in HCV+ than in HCV- patients, increasing with the fibrotic stage of liver disease. We further demonstrated that COX-2 mRNA, protein, and activity were induced in resting and activated core and NS5A transfectants. Both viral proteins induced transcriptional activity of the COX-2 gene promoter whereas core, but not NS5A, exerted an inducer effect on MMP-9 protein levels in cultured hepatocyte derived cells.
CONCLUSIONS: Intrahepatic COX-2, MMP-2, and MMP-9 overexpression is associated with progressive hepatic fibrosis in chronic HCV infection, suggesting their pathogenic role in fibrogenesis. HCV core and NS5A proteins were able to upregulate COX-2 and MMP-9 gene expression in hepatocyte derived cells, providing a potential mechanism for hepatic fibrosis during chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479690      PMCID: PMC1774290          DOI: 10.1136/gut.2003.038364

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  46 in total

Review 1.  Hepatocellular carcinoma: present status and future prospects.

Authors:  Josep M Llovet; Michel Beaugrand
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.

Authors:  N Zhu; A Khoshnan; R Schneider; M Matsumoto; G Dennert; C Ware; M M Lai
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity.

Authors:  Takeya Tsutsumi; Tetsuro Suzuki; Takashi Shimoike; Ryosuke Suzuki; Kyoji Moriya; Yoshizumi Shintani; Hajime Fujie; Yoshiharu Matsuura; Kazuhiko Koike; Tatsuo Miyamura
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

5.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue.

Authors:  D A Kujubu; B S Fletcher; B C Varnum; R W Lim; H R Herschman
Journal:  J Biol Chem       Date:  1991-07-15       Impact factor: 5.157

6.  Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators.

Authors:  N A Callejas; A Castrillo; L Boscá; P Martín-Sanz
Journal:  J Pharmacol Exp Ther       Date:  1999-03       Impact factor: 4.030

7.  Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

Authors:  Hervé Lerat; Masao Honda; Michael R Beard; Kim Loesch; Jiaren Sun; Yan Yang; Michiari Okuda; Rainer Gosert; Shu-Yuan Xiao; Steven A Weinman; Stanley M Lemon
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

8.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines.

Authors:  D A Jones; D P Carlton; T M McIntyre; G A Zimmerman; S M Prescott
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

9.  Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay.

Authors:  K K Young; R M Resnick; T W Myers
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

10.  Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells.

Authors:  C C Pilbeam; H Kawaguchi; Y Hakeda; O Voznesensky; C B Alander; L G Raisz
Journal:  J Biol Chem       Date:  1993-12-05       Impact factor: 5.157

View more
  55 in total

1.  Extracellular Matrix Remodeling and Modulation of Inflammation and Oxidative Stress by Sulforaphane in Experimental Diabetic Peripheral Neuropathy.

Authors:  Passant E Moustafa; Noha F Abdelkader; Sally A El Awdan; Osama A El-Shabrawy; Hala F Zaki
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

Review 2.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

Review 3.  Immunomodulatory effects of transforming growth factor-β in the liver.

Authors:  Hans-Theo Schon; Ralf Weiskirchen
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

4.  Antifibrotic effect of meloxicam in rat liver: role of nuclear factor kappa B, proinflammatory cytokines, and oxidative stress.

Authors:  Memy H Hassan; Mohamed M Ghobara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-31       Impact factor: 3.000

5.  Cyclo-oxygenase 2 expression impairs serum-withdrawal-induced apoptosis in liver cells.

Authors:  Amalia Fernández-Martínez; Belén Mollá; Rafael Mayoral; Lisardo Boscá; Marta Casado; Paloma Martín-Sanz
Journal:  Biochem J       Date:  2006-09-15       Impact factor: 3.857

Review 6.  Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Martine Soell; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mosaad Megahed
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

7.  Betulinic acid exerts anti-hepatitis C virus activity via the suppression of NF-κB- and MAPK-ERK1/2-mediated COX-2 expression.

Authors:  Chun-Kuang Lin; Chin-Kai Tseng; Kai-Hsun Chen; Shih-Hsiung Wu; Chih-Chuang Liaw; Jin-Ching Lee
Journal:  Br J Pharmacol       Date:  2015-08-03       Impact factor: 8.739

8.  Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.

Authors:  Cristina Llorente Izquierdo; Rafael Mayoral; Juana María Flores; Pilar García-Palencia; Carme Cucarella; Lisardo Boscá; Marta Casado; Paloma Martín-Sanz
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

9.  Role of free radicals in liver diseases.

Authors:  Pablo Muriel
Journal:  Hepatol Int       Date:  2009-11-26       Impact factor: 6.047

10.  Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El-Bassiouny; Mona M K Zoheiry; Mona M F Nosseir; Eman G El-Ahwany; Raafat A Ibrahim; Nora E I El-Bassiouni
Journal:  MedGenMed       Date:  2007-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.